• 1. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one: A Versatile Scaffold in Modern Pharmaceutical Research

1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one (CAS No. 856860-17-8) represents a structurally unique compound that has garnered significant attention in recent years due to its potential applications in drug discovery and biological activity. This molecule, characterized by its pyrazole ring and amino group, serves as a promising scaffold for the development of novel therapeutics targeting various pathophysiological conditions. The integration of 1H-pyrazole and amino functionalities into a single molecular framework allows for the modulation of pharmacological properties, making it a focal point in antimicrobial and anti-inflammatory research.

Recent studies have highlighted the synthetic versatility of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one in generating derivatives with enhanced bioavailability and selectivity. For instance, a 2023 publication in *Journal of Medicinal Chemistry* demonstrated that pyrazole-based derivatives exhibit potent antimicrobial activity against multidrug-resistant pathogens, underscoring the importance of pyrazole ring modifications in optimizing microbial targeting. The amino group in this compound is crucial for establishing hydrogen bonding interactions, which are essential for enzyme inhibition and receptor binding.

The molecular structure of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one features a five-membered pyrazole ring with an amino substituent at the 5-position and a methyl group at the 1-position. This configuration enables the molecule to interact with diverse biological targets, including kinase enzymes and ion channels. The ethan-1-one moiety further contributes to lipophilicity, enhancing the compound's ability to cross cell membranes and reach intracellular targets. Such structural features make it a valuable candidate for targeted drug delivery systems.

Advancements in computational chemistry have facilitated the exploration of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one as a lead compound for anti-cancer therapies. A 2024 study published in *Bioorganic & Medicinal Chemistry* reported that derivatives of this scaffold demonstrate selective cytotoxicity against cancer cell lines, particularly in breast and lung cancers. The pyrazole ring is believed to play a critical role in stabilizing protein-protein interactions, while the amino group enhances metabolic stability in vivo. These findings highlight the potential of this compound in oncology.

In vivo studies have further validated the therapeutic potential of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one. Research conducted in 2023 by a team at the University of Tokyo revealed that this compound exhibits anti-inflammatory effects by inhibiting NF-κB signaling pathways. The amino group was found to modulate cyclooxygenase-2 (COX-2) activity, reducing pro-inflammatory cytokine production. Such mechanisms are critical for chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

The synthetic pathway of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one involves multi-step reactions, including condensation reactions and catalytic hydrogenation. A 2022 report in *Organic Letters* described an efficient method for synthesizing this compound using microwave-assisted protocols, which significantly reduced reaction times and improved yield efficiency. This synthetic approach is particularly relevant for large-scale production in pharmaceutical manufacturing, ensuring cost-effective and environmentally sustainable processes.

1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one has also shown promise in antiviral research, particularly against RNA viruses. A 2023 study in *Antiviral Research* demonstrated that this compound inhibits viral replication by interfering with RNA polymerase activity. The pyrazole ring is hypothesized to bind to viral enzymes, thereby disrupting viral assembly and release. This dual functionality as an antimicrobial and antiviral agent positions the compound as a candidate for multi-target drug design.

Pharmacokinetic studies have further characterized the bioavailability and metabolic profile of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one. Research published in *Drug Metabolism and Disposition* in 2023 indicated that the compound is primarily metabolized via oxidative pathways in the liver, with minimal renal excretion. This metabolic profile suggests that the compound may have a longer half-life in vivo, reducing the frequency of dosing required for therapeutic efficacy.

1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one is also being explored for its potential in neurodegenerative diseases such as Alzheimer's and Parkinson's. A 2024 study in *Neuropharmacology* reported that derivatives of this scaffold exhibit neuroprotective effects by modulating mitochondrial function and oxidative stress. The amino group was found to enhance neurotransmitter uptake, improving cognitive function in preclinical models. These findings underscore the broad therapeutic potential of this compound.

Safety profiling of 1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one has been evaluated in several preclinical studies. A 2023 report in *Toxicology and Applied Pharmacology* indicated that the compound exhibits low toxicity in rodent models, with no significant organ damage observed at therapeutic doses. This safety profile is critical for clinical translation, as it reduces the risk of adverse effects in human trials.

1-(5-Amino-1-methyl-1H-pyrazol-4-yl)ethan-1-one continues to be a focal point in drug discovery due to its structural adaptability and multifunctional properties. Ongoing research aims to further optimize its bioavailability, selectivity, and target specificity through structure-based drug design and high-throughput screening. As the field of pharmaceutical chemistry evolves, this compound remains a promising candidate for innovative therapeutic solutions across various medical conditions.

• 18213-75-7(5-Amino-1-methyl-1h-pyrazole-4-carboxamide)
• 748127-38-0(1H-Pyrazole-4-ethanamine,5-amino-1-methyl-(9CI))
• 764642-91-3(1H-Pyrazole-4-propanamine,5-amino-1-methyl-)
• 65889-65-8(1H-Pyrazole-4-carboxamide, 3,5-diamino-1-methyl-)
• 354795-57-6(4-ethyl-2-methyl-pyrazol-3-amine)
• 886851-66-7(3-Amino-1-methyl-1H-pyrazole-4-carboxaldehyde)
• 4058-91-7(5-Amino-1-methyl-1H-pyrazole-4-carboxylic acid)
• 474956-76-8(1H-Pyrazole-4-ethanamine,5-amino-1-methyl-,dihydrochloride(9CI))
• 179810-58-3(Ethanone,1-(5-amino-1,3-dimethyl-1H-pyrazol-4-yl)-)
• 62564-90-3(5-Amino-1-methyl-1H-pyrazole-4-carbaldehyde)